Literature DB >> 28636609

Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa.

John Osei Sekyere1, Daniel Gyamfi Amoako2,3.   

Abstract

Resistance to fluoroquinolones (FQ) is being increasingly reported and found to be mediated by efflux pumps, plasmid-mediated quinolone resistance genes (PMQR) and mutations in gyrA, gyrB, parC and parE. However, studies reporting on FQ resistance mechanisms (FQRM), particularly in Africa, are focused mostly on Salmonella. This study used a whole-genome-based approach to describe FQRM in forty-eight clinical Enterobacteriaceae isolates comprising of Klebsiella pneumoniae (n = 21), Serratia marcescens (n = 12), Enterobacter spp. (n = 10), Citrobacter freundii (n = 3), Escherichia coli (n = 1), and Klebsiella michiganensis (n = 1) with reduced susceptibility to FQ in Enterobacteriaceae. All the isolates exhibited exceptionally high-level resistance (MIC of 4-512mg/L) to all three FQs, which could not be reversed by carbonyl cyanide m-chlorophenyl hydrazine (CCCP), verapamil (VRP) or reserpine (RSP). PMQR genes such as oqxAB (n = 43), aac(6')-Ib-cr (n = 28), and qnr(S1, B1, B2, B9, B49, B66) (n = 23) were identified without transposons or integrons in their immediate environments. Multiple and diverse mutations were found in gyrA (including S83I/Y and T/I83I/T), gyrB, parC and parE, which were clonally specific. There were vertical and horizontal transmission of high-level FQ resistance in Enterobacteriaceae in hospitals in Durban, South Africa, which are mediated by efflux, PMQR genes, and gyrA, gyrB, parC and parE mutations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28636609      PMCID: PMC5479536          DOI: 10.1371/journal.pone.0178888

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


1. Introduction

Until recently, fluoroquinolones (FQ), which were made from the first quinolone called nalidixic acid (NAL), (a by-product of chloroquine synthesis) were very potent and were the most prescribed broad-spectrum antibiotic class for treating fatal bacterial infections [1,2]. They are the only antibiotic class that directly inhibits DNA synthesis/replication by inhibition of DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV (encoded by parC and parE) [1,2]. However, their increased overuse has led to increased resistance among both Gram-negative and Gram-positive bacteria, making them less effective [1,2]. Hence, they are used more in combination therapies with last line antibiotics such as carbapenems, colistin and tigecycline than as monotherapy [3,4]. Contrary to β-lactams that are hydrolysed by β-lactamases to cause resistance [5-7], resistance to FQ is largely mediated by point mutations in the quinolone resistance determining regions (QRDR) of gyrA, gyrB, parC and parE [1,8]. In addition, extrusion by intrinsic efflux pumps and horizontal acquisition of the plasmid-mediated quinolone resistance (PMQR) genes such as qepA, qnr, oqxAB and aac(6’)-Ib-cr have been also implicated in low-level resistance to FQ [1,2,9]. Thus, studies describing FQ resistance mechanisms (FQRM) largely focuses on finding the presence of PMQR genes, evaluating the effect of efflux on FQ resistance as well as determining the presence of mutations in gyrA, gyrB, parC and parE [1,10-12]. Although there are numerous studies characterising the prevalence and molecular epidemiology of FQRM, such studies are largely focused on Salmonella enterica and to a lesser extent, Escherichia coli and Vibrio cholerae through the use of PCR and pulsed field gel electrophoresis (PFGE)-based typing, particularly in Africa and South Africa [1,11-13]. Thus the ability to compare FQ-resistant strains between different countries in Africa is limited and a true genomic characterisation and epidemiology of FQRM, specifically among Enterobacteriaceae is scarce [1]. Due to the ability of enteric bacteria to associate in biofilms and share plasmids among themselves, it is imperative to broaden the scope of research beyond Salmonella to identify other Enterobacteriaceae that are reservoirs of FQ resistance. To our knowledge, there is no study using whole-genome sequencing to (WGS) describe FQRM in Enterobacteriaceae in South Africa and to a large extent, in Africa. To provide a comprehensive description of FQRM among Enterobacteriaceae in Durban, South Africa, this study was undertaken using a large collection of diverse Enterobacteriaceae species with the view of providing a bedrock to facilitate comparative analysis in future studies and enhance meaningful epidemiological conclusions and resolutions. Moreover, an in-depth description of the transfer mechanisms of FQ resistance is important for the arrest and control of FQ-resistant strains in hospitals.

2. Results

2.1 MICs of CIP, NOR, and NAL with and without the inhibitors

The MICS of ciprofloxacin (CIP), norfloxacin (NOR) and nalidixic acid (NAL) were determined for all the isolates and controls both in the absence and presence of efflux pump inhibitors (EPIs) to assess the role of efflux pumps in FQs resistance. The MICs of NAL was very high (>512mg/L) for all the isolates whilst that of CIP and NOR ranged from 4 to 512mg/L, which makes all the isolates very resistant per the EUCAST (2016) breakpoints; MIC of >1 mg/L is defined as resistant (Table 1 and S1 Table) [14]. Most of the isolates had CIP and NOR MICs above 128mg/L.
Table 1

Results of norfloxacin (NOR) and ciprofloxacin (CIP) MIC changes upon adding carbonyl cyanide-m-chlorophenylhydrazine (CCCP), verapamil (VRP) and reserpine (RSP).

IsolateMIC of Norfloxacin (NOR) (mg/L)IMIC of Ciprofloxacin (CIP) (mg/L)
NORNOR + CCCP (Δ)NOR + VRP (Δ)NOR + RSP (Δ)CIPCIP + CCCP (Δ)CIP + VRP (Δ)CIP + RSP (Δ)
E. coli ATCC 259220.030.030.030.030.0075.00750.0040.0075
K. oxytoca ATCC 131780.250.250.1250.250.030.030.0150.03
K. pneumoniae
C(UNN39_S3)51251251264 (8)512512512128 (4)
D(UNN40_S4)>512512512128 (4)512512512128 (4)
I(UNN45_S9)8882 (4)4442 (2)
J(UNN46_S10)512512512128 (4)25625625664 (4)
3_S2256128 (2)51264 (8)256128 (2)25632 (8)
12_S5>512512512128 (4)512512512128 (4)
13_S612812812864 (2)12812812832 (4)
15_S8>512512>512256 (>2)512256 (2)512128 (4)
18_S10256128 (2)51264 (8)256128 (2)25632 (8)
20_S1112812812816 (8)6464648 (4)
21_S12512512512128 (4)25625625664 (4)
29_S13512512512128 (4)25625625664 (4)
30_S1425612812832 (4)25625625664 (4)
32_S15>512512512128 (4)512512512128 (4)
34_S16256128 (2)51264 (8)256128 (2)25632 (4)
35_S17512256 (2)51264 (8)25625625664 (4)
36_S1812812812864 (2)12812812832 (4)
38_S19>512512>512128 (4)256128 (2)25664 (4)
47_S22512256 (2)51264 (8)25625625664 (4)
52_S2612812812864 (2)12812812832 (4)
53_S27512256 (2)51264 (8)25625625664 (4)
S. marcescens
B(UNN38 _S2)512256 (2)51216 (32)256128 (2)128 (2)16 (16)
E(UNN41_S5)>512512512128 (4)512256 (2)256 (2)64 (8)
G(UNN43_S7)51251251232 (16)256128 (2)25664 (4)
K(UNN47_S11)512512512128 (4)25625625664 (4)
L(UNN48_S12)256128 (2)25616 (16)256128 (2)25616 (16)
7_S3512256 (2)64 (8)16 (32)25625632 (8)32 (8)
45_S216464644 (4)3216 (2)324 (8)
56_S29512512512128 (4)25625625664 (4)
59_S30256128 (2)256128 (2)12812812832 (4)
67_S33512256 (2)64 (8)16(32)25625632 (8)32 (8)
68_S3425625625616 (16)6432 (2)648 (8)
71_S36512512512128 (4)25625625664 (4)
Enterobacter speciesII
A (UNN37_S1)25664 (4)64 (4)4 (64)6432 (2)642 (32)
F (UNN42_S6)5125125128 (64)25625625616 (16)
H (UNN44_S8)51251251232 (16)25625625664 (4)
1_S1884 (2)2 (4)8882 (4)
16_S951251264 (8)32 (16)12864 (2)32 (4)8 (16)
43_S20884 (2)2 (4)8882 (4)
49_S243216 (2)16 (2)4 (8)3216 (2)16 (2)2 (16)
55_S281281281288 (16)6464644 (16)
63_S31884 (2)2 (4)8882 (4)
65_S32512512512128 (4)25625625664 (4)
E. coli
10_S4512512256 (2)128 (4)512512512128 (4)
C. freundii
14_S7512256 (2)64 (8)16 (32)25625632 (8)32 (8)
48_S23512256 (2)64 (8)16 (32)25625632 (8)32 (8)
51_2525625625616 (16)6432 (2)648 (8)
K. michangenesis
69_S3512864 (2)8 (16)4 (32)64648 (8)4 (16)

I MICs were interpreted per EUCAST breakpoints for 2016: CIP and NOR Resistance > 1mg/L

IISee Table 2 for species breakdown

I MICs were interpreted per EUCAST breakpoints for 2016: CIP and NOR Resistance > 1mg/L IISee Table 2 for species breakdown
Table 2

Sources and fluoroquinolone/quinolone resistance mechanisms of the Enterobacteriaceae isolates.

Isolate (clone)Specimen typePlasmid-mediated fluoroquinolone resistance genesChromosomal mutations
gyrAgyrBParCparE
K. pneumoniae III
53_S27 (ST101)Urineaac(6’)-ib-cr, OqxA, OqxB,S83Y, D87GD553VS80I, N304SNM
52_S26 (ST101)Pusaac(6’)-ib-cr, OqxA, OqxB, QnrS1
47_S22 (ST1478)Art lineaac(6’)-ib-cr, OqxA, OqxB, QnrB66V855AM144I, E145V, L173H, S558A, L605M, L591V, H592R, K595S, H599Q, V663I, A692TS438D, D475E, L495Q, Q592R, V691IN130T, N209D, S213R, S225C, A242T, I603M
38_S19 (ST101)XIVoqxBS83Y, D87GD553VS80I, N304SNM
36_S18 (ST101)SputumOqxB
35_S17(ST101)UrineOqxB
34_S16(ST101)Pus swab (Trachea)OqxB
32_S15(ST101)Catheter tipaac(6’)-ib-cr, OqxB
30_S14(ST101)UrineOqxB
29_S13(ST2017)Abdominal swabOqxB
21_S12(ST2017)UrineoqxA, oqxB
20_S11(ST2017)Tracheal fluidOqxA, OqxB
18_S10(ST101)urineOqxB
15_S8(ST101)Pus swab (leg)OqxB
13_S6 (ST2016)Xaac(6’)-ib-cr, OqxB
12_S5(ST101)Blood cultureoqxB
3_S2(ST14)UrineAac(6’)-ib-cr, OqxB, OqxA, QnrB1S83Y, D87G, I54VNMS80I
J(UNN46_S10(ST101))Xaac(6’)-ib-cr, OqxBS83Y, D87GD553VS438D, D475E, L495Q, Q592R, V691I
I(UNN45_S9) (ST323)Urineaac(6’)-ib-cr, OqxB, OqxANMVNMN304S
D(UNN40_S4) (ST101)Urineaac(6’)-ib-cr, OqxB, OqxA,S83Y, D87GD553VS438D, D475E, L495Q, Q592R, V691I
C(UNN39_S3) (ST101)Urineaac(6’)-ib-cr, OqxA, OqxB
S. marcescensVI
71_S36 (SA1)Xaac(6’)-lb-cr,S83I, A188T, S171A, V240IT155N, D181E, K206Q, Q696K, A636S, Q692L, I701VT59N, R679Q, Y705H, G753S, A750VNM
68_S34 (SA1)BloodoqXB
67_S33 (SA1)CVP TipoqxB
59_S30 (SA2)urineaac(6’)-ib-cr, QnrS1, oqxB,S83I, A188TT155N, D181E, K206Q, Q696KT59N, A592T, R679Q, Y705H, G753S, A750V
56_S29 (SA2)urineaac(6’)-ib-cr, OqxB
45_S21 (SA1)Tracheal fluidaac(6’)-ib-cr, oqxBS83I, A188T, S171A, V240IT155N, D181E, K206Q, Q696K, A636S, Q692L, I701VT59N, R679Q, Y705H, G753S, A750V
7_S3 (SA1)XoqxB,
L(UNN48_S12) (SA1)Sputumaac(6’)-ib-cr, oqxB
K(UNN47_S11) (SA1)Bloodaac(6’)-ib-cr, oqxB
G(UNN43_S7) (SA1)Bloodaac(6’)-ib-cr, oqxB
E(UNN41_S5) (SA1)CVP TipoqxB
B (UNN38 _S2) (SA1)Tracheal fluidoqxB
Enterobacter species (unless otherwise stated in footnote, species is cloacae)VII
65_S32(ST436)CVCVIII TipoqxB, oqxAA427S, L508QA155TV402A, V582I, N746SR378G
63_S31IXUrineaac(6’)-ib-cr, OqxA, OqxB, QnrB49T83I, G409A, I411VH173L, K206R, D747EE84K, L596M, T746AS592R
55_S28XETAXIaac(6’)-ib-cr, OqxB, OqxA, QnrB49S83YSame as H(UNN44_S8), I144L, S571H, D619E, N622D, A632T, I663V, E723DL151M, F215Y, V402A, T459N, L596M, M621L, H629R, P632T, V636I, I691L, N746SK203T, N205H, S212T, T243S, E475D, Y520H
49_S24XIIUrineaac(6’)-ib-cr, QnrB66, OqxB, OqxA, QnrB9,G409A, I411VSame as 63_S31, A716TNMNM
43_S20 (ST433)XIIIAbdominal fluidaac(6’)-ib-cr, OqxB, OqxA, QnrB49S83I, I112V, L127M, A128SI60V, Q72T, I144L, Q146T, E151Q, D159E, E161D, D359E, Q362L, N366S, D550E, S571H, 5595T, A604T, I610V, N622S, A625T, S635T, E636D, F649C, A656D, Q657G, I663V, E723D, S734A, D746EE205D, T246N, S348T, V402A, M621L, P632A, V636I, S648T, I691L, N746AS212H, N205H, T243S, E475D
16_S9XIVurineaac(6’)-ib-cr, QnrB1, OqxA, OqxBNMSame as 55_S28Same as 55_S28, A467SN205H, K203T, T243S, E475D, Y520H
1_S1(ST108)CVP TipAac(6’)-ib-cr, oqxB, oqxA, QnrB1T408A, A409S, I411V, S412A, I509V, A526S, Q536R, K69IS, D709N, I737V, G759SSame as F(UNN42_S6), T691A, I663V, D359EF215Y, T246N, S348T, T352A, V402A, K427R, Q495L, A527S, L596M, V635I, V636I, S648A, N673S, G685S, I691L, N746K, G747DSame as F(UNN42_S6), M273L
H(UNN44_S8)XVUrineaac(6’)-ib-cr, oqxA, oqxB, QnrB1I60V, Q72T, Q146T, E151Q, E161D, D359E, Q362L, N366S, D550E, A625T, A632T, A656EL151M, E205D, F215Y, S348T, T352A, V402A, Q495L, A527S, L596M, M621L, V635I, V636I, S648A, N673S, G685S, I691L, N746K, G747DN225H, C234R, T243E, E475D, Y520H, M273L, A236E, D237K
F(UNN42_S6) (ST121)XVIUrineaac(6’)-ib-cr, QnrB1, oqxA, oqxB,Same as 1_S1 above plus S83I, D861EI60V, Q72T, Q362L, N366S, A625T, A632T, A696ES80I, L151M, E205D, F215Y, S272T, S348T, T352A, V402A, K427R, Q495L, A527S, L596M, M621L, V635I, V636I, S648A, N673S, G685S, I691L, N746K, G747D, D583EN225H, S232T, T243E, E475D, T512A, Y520H, M602V
A(UNN37_S1)XVIIUrineaac(6’)-ib-cr, oqxB, oqxA, QnrS1, QnrB1G409A, I411VSame as 49_24NMNM
C. freundiiXVIII
51_S25 (NKXIX)sputumaac(6’)-ib-cr, QnrB49, QnrS1T83I, N535S, N691S, N709D, G728E, E729K, E758A, S759E, G767AH417L, A576S, A579L, A616P, V642M, R688H, A692TS80I, E204D, N458S, E470D, F690YNM
48_S23 (ST63)Catheter tipAac(6’)-ib-cr, QnrB2, QnrS1
14_S7sputumAac(6’)-ib-cr, QnrB38T83IL162M, A692TE204D, F690Y
E. coliXX
10_S4 (ST167)Urine-XXIS58L, D62N, E653D, S803AD185ES80I, E475D, P677LI76V, S458A
K. michiganensisXXII
69_S35 (ST170)Urineaac(6’)lb-cr, oqxB, oqxA, QnrS1I83TNMS80RNM

IIIK. pneumoniae ATCC 13883 (PRJNA244567) was used as reference strain in the comparative genome analysis

IVData missing; VNo mutation

VIS. marcescens strain CDC_813–60 (ATCC 13880) (JOVM00000000/ PRJNA244355) was used as reference strain to find amino acid mutations

VIIUnless otherwise stated in footnote, E. cloacae ATCC 13047 (CP001918.1) was used as reference strain in the comparative genomics

VIIICentral venous catheter

VIX Enterobacter asburiae: E. asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations

X Enterobacter kobei: E. kobei strain 35730 (JZYS01000016.1) or E. cloacae ATCC 13047 (CP001918.1) served as reference strains for amino acid mutations.

XI Endotracheal aspirate

XIIEnterobacter asburiae: Enterobacter asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations

XIII Enterobacter cloacae complex “Hoffman cluster IV”

XIVEnterobacter kobei: E. kobei strain 35730 (JZYS01000016.1) or E. cloacae ATCC 13047 (CP001918.1) served as reference strains for amino acid mutations.

XVEnterobacter cloacae complex “Hoffman cluster III”

XVIEnterobacter species

XVIIEnterobacter asburiae: Enterobacter asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations.

XVIIIC. freundii ATCC 8090 = MTCC 1658 (PRJNA177199) was used as reference strain for the comparative genomics to find amino acid mutations.

XIXMLST unknown

XXEscherichia coli ATCC 25922 (CP009072) was used as subject in the comparative genomics analysis to find the amino acid mutations.

XXINo PMQR (plasmid-mediated quinolone resistance) gene found

XXIIKlebsiella michiganensis KCTC 1686 (CP003218.1) was used as reference strain for this comparative genomic analysis to find amino acid mutations.

An MIC fold change of ≥8 was adopted as significant [15]. Hence, none of the inhibitors viz., carbonyl cyanide-m-chlorophenylhydrazine (CCCP), verapamil (VRP) and reserpine (RSP) could affect the MICs of NAL (Table 1 and S1 Table) significantly i.e. had a fold change of ≥8, albeit fold changes of 2–4 were recorded in S. marcescens, Enterobacter spp., C. freundii and K. michiganensis. CCCP, followed by VRP, had the least effect on the MICs of the antibiotics in all the species whilst RSP had the most effect; majority of the MIC fold changes effected by RSP were significant (Table 1 and S1 Table). RSP resulted in more significant MIC fold changes in NOR (n = 24) than in CIP (n = 16) and was the only EPI that effected a consistently significant MIC fold-change reduction in all the isolates except for NAL (S1 Table). Among the species, E. coli had no significant MIC fold change and only RSP resulted in significant MIC fold changes in K. pneumoniae; however, both RSP and VRP resulted in significant fold changes in the remaining species. None of the inhibitors could reverse resistance to any of the antibiotics. The MICs (of either CIP and/or NOR) of only 25 isolates were significantly affected by both VRP and RSP (Table 1).

2.2 Species frequency and distribution of plasmid-mediated quinolone resistance (PMQR) genes

The presence and frequency distribution of each PMQR gene was assessed in each isolate’ genome sequence. No qepA gene was found in any of the isolates. Moreover, no PMQR gene was found in the E. coli strain. OqxAB, aac(6’)-Ib-cr, and qnr(S1, B1, B2, B9, B49, B66), were found in 43, 28, and 23 isolates respectively (Fig 1, Table 2). OqxA occurred in 20 isolates whilst oqxB was found in 43; hence, whilst oqxB alone was found in 23 isolates, oqxA was always found alongside oqxB. OqxA and oqxB occurred together in 20 isolates, 10 of which were Enterobacter spp., 9 were K. pneumoniae and one was K. michiganensis (Fig 1, Table 3). There was no oqxAB in C. freundii and no oqxA was present in S. marcescens. Aac(6’)-Ib-cr was commonest in Enterobacter spp. (n = 9), K. pneumoniae (n = 8), and S. marcescens (n = 7) respectively. Qnr genes were commonly found in Enterobacter spp. (n = 11 qnr genes), C. freundii (n = 6 qnr genes) and K. pneumoniae (n = 4 qnr genes), with qnrS1 (n = 7), qnrB1 (n = 6) qnrB49 (n = 4) being the most common variants (Tables 2 and 3).
Fig 1

Frequency and distribution of plasmid-mediated quinolone resistance (PMQR) genes per specie.

PMQR genes occurred in all isolates except E. coli. oqxAB genes were the most common occurring PMQR gene(s) followed by aac(6’)-Ib-cr and qnr genes. oqxAB was common in K. pneumoniae whilst aac(6’)-Ib-cr and qnr were dominant in Enterobacter spp.

Table 3

Frequency and distribution of plasmid-mediated fluoro/-quinolone resistance (PMQR) genes in the Enterobacteriaceae isolates.

Plasmid-mediated quinolone resistance (PMQR) geneGene variantsFrequency (h) of occurrence per specieTotal frequency (n = 48)
K. pneumoniae (n = 21)S. marcescens (n = 12)Enterobacter spp. (n = 10)C. freundii (n = 3)E. coli (n = 1)K. michiganensis (n = 1)
Aac(6’)-Ib-cr-87930128
QnrQnrS12112017
QnrB11050006
QnrB490031004
QnrB661010002
QnrB20001001
QnrB90011002
QnrB380001001
OqxABoqxA901000120
oqxB21111000143

Frequency and distribution of plasmid-mediated quinolone resistance (PMQR) genes per specie.

PMQR genes occurred in all isolates except E. coli. oqxAB genes were the most common occurring PMQR gene(s) followed by aac(6’)-Ib-cr and qnr genes. oqxAB was common in K. pneumoniae whilst aac(6’)-Ib-cr and qnr were dominant in Enterobacter spp. IIIK. pneumoniae ATCC 13883 (PRJNA244567) was used as reference strain in the comparative genome analysis IVData missing; VNo mutation VIS. marcescens strain CDC_813–60 (ATCC 13880) (JOVM00000000/ PRJNA244355) was used as reference strain to find amino acid mutations VIIUnless otherwise stated in footnote, E. cloacae ATCC 13047 (CP001918.1) was used as reference strain in the comparative genomics VIIICentral venous catheter VIX Enterobacter asburiae: E. asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations X Enterobacter kobei: E. kobei strain 35730 (JZYS01000016.1) or E. cloacae ATCC 13047 (CP001918.1) served as reference strains for amino acid mutations. XI Endotracheal aspirate XIIEnterobacter asburiae: Enterobacter asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations XIII Enterobacter cloacae complex “Hoffman cluster IV” XIVEnterobacter kobei: E. kobei strain 35730 (JZYS01000016.1) or E. cloacae ATCC 13047 (CP001918.1) served as reference strains for amino acid mutations. XVEnterobacter cloacae complex “Hoffman cluster III” XVIEnterobacter species XVIIEnterobacter asburiae: Enterobacter asburiae L1 (CP007546.1) was used as reference strain for the comparative genomics to find amino acid mutations. XVIIIC. freundii ATCC 8090 = MTCC 1658 (PRJNA177199) was used as reference strain for the comparative genomics to find amino acid mutations. XIXMLST unknown XXEscherichia coli ATCC 25922 (CP009072) was used as subject in the comparative genomics analysis to find the amino acid mutations. XXINo PMQR (plasmid-mediated quinolone resistance) gene found XXIIKlebsiella michiganensis KCTC 1686 (CP003218.1) was used as reference strain for this comparative genomic analysis to find amino acid mutations. No transposon or integron was found in the immediate environment of the qnr and aac(6’)-Ib-cr genes. The truncated nature of the plasmid contigs made it impossible to link the PMQR genes to particular plasmids or replicon/incompatibility types.

2.3 Multi locus sequence typing (MLST) and S. marcescens typing

The MLST of the isolates are shown in Table 2 and it can be seen that the isolates were very multiclonal, albeit many K. pneumoniae strains (n = 14) were of sequence type (ST) 101. The MLST of K. michiganensis was determined using that of K. oxytoca due to misidentification of the former as K. oxytoca. Alignment of the dnaA, fusA, gyrB, leuS, pyrG, rplB, and rpoB housekeeping genes of all the 12 S. marcescens isolates resulted in 10 of the isolates being classified into the same clone (i.e. SA1) and two of the remaining being grouped into SA2 clone. Isolates of each clone showed no variation from the reference sequences of housekeeping genes of their respective clones. The SA2 clone only differed from SA1 clone at the nucleotide level in dnaA and leuS by a single (T106C) and double (A7G and A91G) silent single nucleotide polymorphisms (SNPs) respectively

2.4 Mutations in gyrA, gyrB, parC and parE

The sequences of gyrA, gyrB, parC and parE were analysed to determine the presence of mutations that could account for the high-level FQ resistance as mutations in these four genes have been incriminated in high-level FQ resistance. The mutations in gyrA, gyrB, parC and parE mostly occurred in a manner that reflected the clonality of the strains i.e. the mutations in all the genes were mostly clonally related. For instance, K. pneumoniae ST101 and ST2017 had the same mutations in all the genes except for parC at which only three ST101 strains (J, D and C) differed. The mutations in K. pneumoniae ST1478, ST323 and ST14 were unique. The clonal nature of the mutations was more obvious with S. marcescens in which all SA1 and all SA2 clones had the same mutations for these genes within their members. The close relation between SA1 and SA2 clones were further underscored by the similarity and few differences in the mutations observed in their gyrA, gyrB, parC and parE genes. This observation corroborated the correctness of our typing system. Within the Enterobacter spp. and C. freundii isolates, the uniqueness of their gyrA, gyrB, parC and parE mutations was but a reflection of their different species or clones. However, C. freundii isolates 51_S25 and 48_S23, except isolate 14_S7, had same mutations in gyrB, parC and parE. Positions 83 in gyrA was a common mutation position in many isolates and species whilst mutations at position 80 in parC was common in C. freundi, E. coli, Enterobacter spp,. K. pneumoniae and K. michiganensis. No parE mutations were found in K. pneumoniae (except in 47_S22), S. marcescens, C. freundii and K. michiganensis (Table 2).

3. Discussion

The importance of this study is underscored by the discovery that there is a substantial number of high-level fluoroquinolone resistance among clonal and multiclonal Enterobacteriaceae circulating in hospitals in Durban, South Africa. This is evinced by the exceptionally high-level of MICs, mostly from 64mg/L to >512mg/L that was recorded among isolates of all species (Table 1 and S3 Table). To our knowledge, no study in South Africa or Africa has discovered such a number of high-level FQ-resistant Enterobacteriaceae with multiple mechanisms of FQ resistance, albeit not all the collected 82 isolates were analysed. This is a rather disturbing observation given the importance of FQ in the management of several bacterial infections in South Africa and the importance of South Africa as a destination for many medical tourists from Africa and Europe [1,4]. To determine the role of efflux pumps as mechanisms underlying this high-level FQ resistance, the isolates were grown in the presence of sub-MICs of CCCP, RSP and VRP. Interestingly, CCCP, a protonophore that indirectly reduce efflux pumps activity by reducing ATP production and unbalancing the electrochemical gradient could not significantly affect the isolates’ MICs. Gram-negative bacteria, including Enterobacteriaceae, are known to have ABC-type efflux pumps that are directly powered/energised by ATP hydrolysis and secondary transporters (sodium-proton symporters) such a MATE-, SMR-, MFS- and RND-type efflux pumps that are powered by the proton motive force (PMF) [16-18]. Hence, the inability of CCCP to reduce the FQ MICs is rather surprising but it shows that efflux pumps affected by CCCP were not involved in resistance to CIP, NOR and NAL. VRP has been shown recently to affect MATE-type efflux pumps by directly blocking the pumps channels [17,15]. Subsequently, we are convinced that MATE-type efflux pumps were involved in conferring resistance to CIP (n = 5) and NOR (n = 6) in a few of the isolates affected by VRP (Table 1). Moreover, it can be concluded that RSP, which is believed to affect RND-type efflux pumps in Gram-negative bacteria [15,19,20], was mostly involved in reducing the MICs of CIP (n = 16) and NOR (n = 24) significantly in many of the isolates. Nevertheless, it must be borne in mind that in all a total of 25 isolates, which is approximately half of the total sample size, were affected by the inhibitors, suggesting that efflux as a mechanism of FQ resistance, was present in one out of every two isolates. This implicating of efflux as a FQRM in approximately half of the isolates is comparable to five studies involving FQ resistance, three of which involved Salmonella [9,10,21], one involved Vibrio cholerae [13]and the last involved Aeromonas veronii and A. hydrophila [12]. Out of these five studies, efflux was implicated as a FQRM in three [9,10,13] whilst they were found not to be involved in two studies [12,21]. Thus, efflux is not always a mechanism of resistance to FQ, albeit an important one. That the inhibitors were unable to reverse FQ resistance in any of the isolates is a testimony that other mechanisms other than efflux was involved [21]. Annotation of the WGS data showed that the most predominant PMQR was oqxAB, which has never been reported as a FQRM in any study in South Africa or Africa as far as we are concerned [1]. This is possibly because PCR has been used in gene-targeted amplification and sequencing, which has not involved the search for oqxAB genes; this stresses the need to incorporate WGS into antibiotic resistance research in Africa [1]. Interestingly, oqxA were not as prevalent as oqxB in the isolates and a pattern or correlation could not be established between their presence and the MICs of the isolates. However, as suggested by other authors [22,23], we also hypothesise that oqxB can work through acrA in the absence of oqxA as oqxAB has been shown to be a supplementary resistance mechanism to acrAB and its increased expression is dependent on a functional acrAB [22,23]. Hence, oqxAB is adding up to other mechanisms to increase the FQ resistance in the isolates and cannot be a major mechanism, particularly when equally or much higher MICs were recorded in strains (e.g. E. coli and C. freundii vis-à-vis S. marcescens and Enterobacter spp.) in which they were absent (Table 2). The second most dominant PMQR gene was aac-(6’)-Ib-cr, which makes this the first study to report on the presence of this gene as a FQRM in Enterobacteriaceae in South Africa. However, this gene has been implicated in FQ resistance in E. coli in Nigeria and a few other African countries [1]. The qnr genes were the least prevalent of the PMQR genes although they are the only PMQR genes to have been reported already in S. Africa and are commonly identified in other African countries [1,12,21]. The commonest variants of the qnr gene identified in this study were the qnrS1, qnrB1 and qnrB49, which agrees with a study by Smith et al. [10] involving Salmonella and by Chenia [12] involving A. veronii and A. hydrophila that found only qnrS1 and qnrB and qnrS respectively. However, Chenia found a higher percentage of qnrB (41%) than qnrS (24%) from freshwater fish whilst we found qnrS1 to be higher than qnrB in clinical samples. There is the need to undertake further surveillance and molecular epidemiology to assess the possibility of these qnr genes being transferred from freshwater foods to humans or of human activities being the source of these resistance genes in freshwater and the environment as has been recently reported in China where PMQR genes in high numbers were found in Aeromonas spp. from rivers contaminated by hospital and aquaculture effluents [2,12]. On the whole, more studies have implicated mutations in gyrA, gyrB, parC and parE as the major mechanism of FQ resistance as the PMQR genes only mediate low-level FQ resistance [9-11,13]. This can be seen in our findings in which mutations in these four genes (except in parE in most isolates) were found in all isolates as compared to the PMQR genes that were not found in all strains. The numerous nature of the mutations observed in the individual genes as well as collectively in all four genes will surely add up to make the strains highly resistant as recorded. The common mutations seen per clone testifies to the clonality of the isolates and authenticates our typing scheme, particularly in S. marcescens. One of the commonest gyrA mutation recorded in literature is Ser83Ile or Ser83Tyr, which was also found in our strains (Table 2). Chenia [12] found Ser80Ile in the parC of her A. hydrophila/veronii strains and this was also found among our isolates. As the mechanism of action of FQ involves the DNA gyrase and topoisomerase IV, it is reasonable that mutations in genes encoding these FQ targets should mediate high-level FQ resistance [1,2]. Hence, we conclude that high-level FQ resistance in Enterobacteriaceae in South Africa is mainly mediated by numerous and diverse mutations in gyrA, gyrB, parC and parE, in synergy with efflux upregulation and PMQR genes, and that these highly resistant strains are being disseminated vertically by clonal and multiclonal expansion and horizontally via plasmids in hospitals. Given that the use of other antibiotics can select for PMQR genes [8], the need for antibiotic stewardship is exceptionally important to prevent further escalation of this menace.

4. Materials and methods

4.1 Ethical approval

The Biomedical Research Ethics Committee of the University of KwaZulu-Natal approved this study under the reference number BE040/14.

4.2 Bacterial strains

From a collection of 82 Enterobacteriaceae isolates with reduced susceptibility to FQ, which were collected from a private pathology laboratory in Durban, South Africa between 2012 and 2013, 48t isolates comprising of Klebsiella pneumoniae (n = 21), Serratia marcescens (n = 12), Enterobacter spp. (n = 10), Citrobacter freundii (n = 3), Klebsiella michiganensis (n = 1), and Escherichia coli (n = 1) that were fully FQ-resistant per further micro-broth dilution (MIC) testing, were selected. Disc diffusion with ciprofloxacin (CIP), norfloxacin (NOR), and nalidixic acid (NAL) was used to identify and collate these 82 isolates in the pathology laboratory, where all isolates with reduced susceptibility to FQ were included; however, further confirmatory testing with MIC showed that only 48 were fully FQ-resistant per EUCAST (2016) breakpoints [14,24]. Hence, only the 48 isolates were included. The isolates were presented by 10 different hospitals to the private pathology laboratory and were obtained from patients of both sex between the ages of 2 months and 83 years. E. coli ATCC 25922 and K. oxytoca ATCC 13178 were used as controls in the antibiotic sensitivity testing/screening (S2 Table). Identification of the isolates were initially done with Vitek II and confirmed by NCBI BLAST and NCBI’s ANI report of the whole genome sequence of the isolates. Thus, the Enterobacter spp. were identified as Enterobacter cloacae (n = 2), E. asburiae (n = 3), E. kobei (n = 2), Enterobacter cloacae complex “Hoffman cluster IV” (n = 1), Enterobacter cloacae complex “Hoffman cluster III” (n = 1), and Enterobacter sp. (n = 1).

4.3 Minimum inhibitory concentrations (MICs) of CIP, NOR, NAL in the absence and presence of CCCP, reserpine (RSP) and verapamil (VRP): Evaluating the effect of efflux on fluoroquinolone resistance

Pure powders of CIP, NOR, NAL, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), reserpine (RSP) and verapamil (VRP) were purchased from Sigma Aldrich (St. Louis, MO, USA) and used for the broth micro dilution assays. MIC determination and results interpretation for CIP, NOR and NAL were done according to EUCAST guidelines and breakpoints (2016) [14]. Deionized water was used to make VRP solutions whilst RSP was prepared in dimethyl sulfoxide (DMSO) and CCCP in 50% methanol (v/v) [25]. Cation-adjusted Mueller Hinton broth was used to determine the minimum inhibitory concentrations (MICs) of CIP, NOR, NAL, and VRP. All solutions were prepared on the day of the experiment and kept protected from the light. In determining the effect of CCCP, RSP and VRP on CIP, NOR and NAL MICs, a sub-MIC (i.e. 0.5 × MIC) of CCCP, RSP and VRP viz., 8, 256 and 256mg/L were used respectively whilst serially increasing the concentrations of the antibiotics to determine the change in MICs (Table 1 and S1 Table). A sub-MIC was used to reduce the possibility of CCCP, RSP and VRP killing the cells and interfering with the true MIC of the antibiotic-inhibitor combination. CCCP was used as a protonophore to assess its effects on the antibiotics’ MICs through a reduction in efflux activity and disruption of the transmembrane electrochemical potential/gradient. It acts by unbalancing the transmembrane proton gradient, reducing ATP production and indirectly inhibiting efflux activity [16]. RSP and VRP are broad spectrum efflux inhibitors that are commonly used in efflux inhibition experiments. They were used in this study to assess their effect on the antibiotics’ MIC through inhibition of RND and MATE efflux pumps respectively [16,17,19,20].

4.4 Genomic DNA extraction, library preparation and whole genome sequencing

Genomic DNA (gDNA) of the isolates were extracted using the GenElute Bacterial Genomic DNA kit (Sigma Aldrich, St. Louis, MO, USA) per the manufacturer’s instructions. The Qubit and Nanodrop were used to determine the concentrations and purity of extracted gDNA. The quality and integrity of the purified gDNA were confirmed by performing gel electrophoresis before proceeding to library generation. Libraries were quantified on the Bioanalyzer (Agilent Technologies) and combined in an equimolar mixture. A nanogram of gDNA was used as input for the Nextera XT kit (Illumina) to generate 300 bp paired-end libraries followed by sequencing on an Illumina MiSeq platform; a genome coverage of 20-90x was generated for all the isolates [6,26,27] (S3 Table).

4.4 Genomic sequencing analysis

Raw sequence reads of the isolates were adaptor- and quality-trimmed using Trimmomatic [28] and deposited at sequence read archive (SRA) under project number PRJNA287968. The raw reads were assembled with SPAdes 3.9 (https://cge.cbs.dtu.dk/services/SPAdes/) and contigs smaller than 200 bps were removed. The resulting fasta files were deposited at Genbank under the bioproject PRJNA287968. Annotation of the whole genome to determine plasmid-mediated fluoroquinolone resistance (PMQR) genes and chromosomal-borne gyrA, gyrB, parC and parE genes was done with ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) and Prokaryotic Genome Annotation Pipeline (PGAP) (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/) respectively [6,29].

4.5 Bioinformatic analysis

MLST of the isolates were determined using MLST 1.7 pipeline at the Center for Genomic Epidemiology (https://cge.cbs.dtu.dk/services/MLST/). The PMQR genes (aac(6’)-Ib-cr, qepA, qnr and oqxAB) were tabulated and their genetic support/environment, namely transposons and integrons, were searched for using the annotations provided by PGAP. Translated nucleotide Basic Local Alignment Search Tool [tBLASTn] was used to search for genetic elements in the immediate environment of the aac(6’)-Ib-cr, and qnr genes. Typing of the S. marcescens isolates was done in-house using seven house-keeping genes that had been used for typing Enterobacter cloacae.: dnaA, fusA, gyrB, leuS, pyrG, rplB, and rpoB [30]. The same housekeeping genes in each S. marcescens isolate were aligned to each other in a gene-gene format using nucleotide BLAST [BLASTn] and SNPs were called for all seven genes. A single SNP in any of the genes was used as a cut-off for categorising the isolates into different clones. Mutations in the chromosomal-borne gyrA, gyrB, parC and parE genes were determined using tBLASTn to call SNPs in these genes. Fluoro/-quinolone susceptible reference/type strains that were used for each species were as follows: K. pneumoniae ATCC 13883 (PRJNA244567) for K. pneumoniae; S. marcescens strain CDC_813–60 (ATCC 13880) (JOVM00000000/ PRJNA244355) for S. marcescens; E. cloacae ATCC 13047 (CP001918.1) for all Enterobacter spp. except E. asburiae and gyrA in E. kobei; Enterobacter asburiae L1 (CP007546.1) for E. asburiae; E. kobei strain 35730 (JZYS01000016.1) or E. cloacae ATCC 13047 (CP001918.1) for E. kobei; C. freundii ATCC 8090 = MTCC 1658 (PRJNA177199) for C. freundii; E. coli ATCC 25922 (CP009072) E. coli; Klebsiella michiganensis KCTC 1686 (CP003218.1) for K. michiganensis. For gyrB, parC and parE in E. kobei, E. cloacae type strain was used as the reference strain as the E. kobei’s reference strain returned no gyrB, parC and parE genes when it was called/searched with BLAST+.

4.6 Data analysis

An MIC fold change was defined as the ratio of the MIC of antibiotic and inhibitor to that of the antibiotic alone. A fold change of ≥8 was deemed as significant and indicative of efflux activity [15]. Where the MIC was >512, an absolute value of 512 was used, specifically for NAL (S1 Table). The frequency and distribution of the PMQR genes per species were tabulated and translated into a graph (Fig 1).

MICs of inhibitors alone and of nalidixic acid (NAL) MIC changes upon adding carbonyl cyanide-m-chlorophenylhydrazine (CCCP), verapamil (VRP) and reserpine (RSP).

(DOC) Click here for additional data file.

Antimicrobial susceptibility (disc diffusion) results for ciprofloxacin, norfloxacin and nalidixic acid on the Enterobacteriaceae isolates.

(DOC) Click here for additional data file.

Genomic features of the sequenced Enterobacteriaceae isolates.

(DOC) Click here for additional data file.
  26 in total

1.  Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae.

Authors:  Mark Veleba; Thamarai Schneiders
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  Review of established and innovative detection methods for carbapenemase-producing Gram-negative bacteria.

Authors:  J Osei Sekyere; U Govinden; S Y Essack
Journal:  J Appl Microbiol       Date:  2015-09-24       Impact factor: 3.772

3.  Genetic characterization of multidrug-resistant, extended-spectrum- β-lactamase-producing Vibrio cholerae O1 outbreak strains, Mpumalanga, South Africa, 2008.

Authors:  Husna Ismail; Anthony M Smith; Arvinda Sooka; Karen H Keddy
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

4.  In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.

Authors:  Anna Ribera; Angels Jurado; Joaquim Ruiz; Francesc Marco; Oscar Del Valle; Josep Mensa; Josep Chaves; Gonzalo Hernández; M Teresa Jiménez de Anta; Jordi Vila
Journal:  Diagn Microbiol Infect Dis       Date:  2002-02       Impact factor: 2.803

5.  Prevalence and characterization of plasmid-mediated quinolone resistance genes in Aeromonas spp. isolated from South African freshwater fish.

Authors:  Hafizah Yousuf Chenia
Journal:  Int J Food Microbiol       Date:  2016-04-27       Impact factor: 5.277

6.  Identification of acquired antimicrobial resistance genes.

Authors:  Ea Zankari; Henrik Hasman; Salvatore Cosentino; Martin Vestergaard; Simon Rasmussen; Ole Lund; Frank M Aarestrup; Mette Voldby Larsen
Journal:  J Antimicrob Chemother       Date:  2012-07-10       Impact factor: 5.790

Review 7.  Current State of Resistance to Antibiotics of Last-Resort in South Africa: A Review from a Public Health Perspective.

Authors:  John Osei Sekyere
Journal:  Front Public Health       Date:  2016-09-30

8.  Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.

Authors:  Alexander L Greninger; Som S Chatterjee; Liana C Chan; Stephanie M Hamilton; Henry F Chambers; Charles Y Chiu
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

9.  Trimmomatic: a flexible trimmer for Illumina sequence data.

Authors:  Anthony M Bolger; Marc Lohse; Bjoern Usadel
Journal:  Bioinformatics       Date:  2014-04-01       Impact factor: 6.937

10.  High Prevalence of Plasmid-Mediated Quinolone Resistance and IncQ Plasmids Carrying qnrS2 Gene in Bacteria from Rivers near Hospitals and Aquaculture in China.

Authors:  Yanping Wen; Xiaoying Pu; Wei Zheng; Guang Hu
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

View more
  16 in total

1.  1,4,7-Triazacyclononane Restores the Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacteriaceae: Exploration of Potential Metallo-β-Lactamase Inhibitors.

Authors:  Anou M Somboro; Daniel G Amoako; John Osei Sekyere; Hezekiel M Kumalo; René Khan; Linda A Bester; Sabiha Y Essack
Journal:  Appl Environ Microbiol       Date:  2019-01-23       Impact factor: 4.792

2.  Genomic Investigation into the Virulome, Pathogenicity, Stress Response Factors, Clonal Lineages, and Phylogenetic Relationship of Escherichia coli Strains Isolated from Meat Sources in Ghana.

Authors:  Frederick Adzitey; Jonathan Asante; Hezekiel M Kumalo; Rene B Khan; Anou M Somboro; Daniel G Amoako
Journal:  Genes (Basel)       Date:  2020-12-14       Impact factor: 4.096

3.  Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence.

Authors:  Jing Yang; Haiyan Long; Ya Hu; Yu Feng; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2021-12-01       Impact factor: 50.129

Review 4.  Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.

Authors:  Miklos Fuzi; Dora Szabo; Rita Csercsik
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

5.  Genomic insights into nitrofurantoin resistance mechanisms and epidemiology in clinical Enterobacteriaceae.

Authors:  John Osei Sekyere
Journal:  Future Sci OA       Date:  2018-02-27

6.  Small Klebsiella pneumoniae Plasmids: Neglected Contributors to Antibiotic Resistance.

Authors:  Maria S Ramirez; Andrés Iriarte; Rodrigo Reyes-Lamothe; David J Sherratt; Marcelo E Tolmasky
Journal:  Front Microbiol       Date:  2019-09-20       Impact factor: 5.640

Review 7.  Mechanistic Insight into Antimicrobial and Antioxidant Potential of Jasminum Species: A Herbal Approach for Disease Management.

Authors:  Acharya Balkrishna; Akansha Rohela; Abhishek Kumar; Ashwani Kumar; Vedpriya Arya; Pallavi Thakur; Patrik Oleksak; Ondrej Krejcar; Rachna Verma; Dinesh Kumar; Kamil Kuca
Journal:  Plants (Basel)       Date:  2021-05-28

8.  First Report of a Whole-Genome Shotgun Sequence of a Clinical Enterococcus faecalis Sequence Type 6 Strain from South Africa.

Authors:  Nontombi Marylucy Mbelle; Nontuthuko Excellent Maningi; Vhudzani Tshisevhe; Lesedi Modipane; Daniel Gyamfi Amoako; John Osei Sekyere
Journal:  Genome Announc       Date:  2017-12-14

9.  Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.

Authors:  John Osei Sekyere
Journal:  Microbiologyopen       Date:  2018-01-18       Impact factor: 3.139

10.  Genomic Analysis of Carbapenemase-Producing Extensively Drug-Resistant Klebsiella pneumoniae Isolates Reveals the Horizontal Spread of p18-43_01 Plasmid Encoding blaNDM-1 in South Africa.

Authors:  Yogandree Ramsamy; Koleka P Mlisana; Mushal Allam; Daniel G Amoako; Akebe L K Abia; Arshad Ismail; Ravesh Singh; Theroshnie Kisten; Khine Swe Han; David J Jackson Muckart; Timothy Hardcastle; Moosa Suleman; Sabiha Y Essack
Journal:  Microorganisms       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.